<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437892</url>
  </required_header>
  <id_info>
    <org_study_id>7948</org_study_id>
    <nct_id>NCT00437892</nct_id>
  </id_info>
  <brief_title>Statins to Reduce D-dimer Levels in Patients With Venous Thrombosis</brief_title>
  <official_title>The Effect of Statins on D-dimer Levels in Patients With a Previous Venous Thromboembolic Event</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi dell'Insubria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi dell'Insubria</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elevated levels of D-dimer, a marker of procoagulant state, have been identified as a marker
      of an increased risk of recurrent VTE. Statins have proven antithrombotic properties, as
      suggested by the reduction of several prothrombotic markers, including D-dimer, in patients
      at high risk of arterial thrombosis. Such antithrombotic properties could also be observed in
      patients at high risk of venous thrombosis. Aim of the study is to assess the effect of
      statins on D-dimer levels in patients with previous VTE after oral anticoagulant treatment
      withdrawal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a single episode of idiopathic VTE (either DVT or pulmonary embolism) who
      received at least 6 months of adequate treatment with oral anticoagulants, for whom treatment
      withdrawal is planned, and with LDL cholesterol levels of equal to or greater than 130 mg/dL
      will be randomized to either atorvastatin, 40 mg, 1 tablet daily and lipid lowering diet or
      lipid lowering diet for 3 months. On the day of oral anticoagulant treatment withdrawal (Day
      0), enrolled patients will undergo measurement of plasma D-dimer. At 30 days ± 3 (Day 30),
      patients will undergo measurement of D-dimer, CK, LDH, ALAT e ASAT and clinical evaluation.
      At 90 days ± 7 (Day 90), patients will undergo measurement of D-dimer, total cholesterol, HDL
      cholesterol, LDL cholesterol, and triglycerides ed clinical evaluation, CK, LDH, ALAT e ASAT.
      At 6 months ± 1 (Day 180), patients will undergo clinical evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Competitive trials and slow recruitment rate
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with elevated D-dimer at day 90</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with elevated D-dimer levels at Day 30;</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with elevated D-dimer levels at Day 0 and subsequent normalization of D-dimer levels at Day 30 and Day 90;</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with recurrent VTE</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin and lipid lowering diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>lipid lowering diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>tablets, 40 mg day, 3 months</description>
    <arm_group_label>Atorvastatin and lipid lowering diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>tablets, 40 mg once daily</description>
    <arm_group_label>Atorvastatin and lipid lowering diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>diet</intervention_name>
    <description>daily</description>
    <arm_group_label>lipid lowering diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>diet</intervention_name>
    <description>daily diet</description>
    <arm_group_label>Atorvastatin and lipid lowering diet</arm_group_label>
    <arm_group_label>lipid lowering diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with a single episode of idiopathic VTE (either DVT or pulmonary
             embolism) who received at least 6 months of adequate treatment with oral
             anticoagulants, for whom treatment withdrawal is planned, and with LDL cholesterol
             levels of equal to or greater than 130 mg/dL.

        Exclusion Criteria:

          -  Age below 18 years,

          -  Pregnancy or puerperium,

          -  Active malignancy,

          -  Need for other anticoagulant treatments (unfractionated heparin, low molecular weight
             heparin),

          -  Presence of transient risk factors for VTE [recent (&lt; 3 months) surgery,

          -  Trauma,

          -  Fractures,

          -  Acute medical disease with immobilization,

          -  Pregnancy or use of oral contraceptives],

          -  Contraindications to statin therapy,

          -  Chronic renal failure (defined by creatinine clearance &lt; 30 mL/min),

          -  Ongoing treatment with statins or fibrates,

          -  Major indication to statin therapy [history of cardiovascular disease, diabetes,
             elevated cardiovascular risk according to the ATP III criteria(19)],

          -  Life expectancy of less than 6 months,

          -  Geographic inaccessibility,

          -  Concomitant enrolment in another clinical trial,

          -  Refused informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Ageno</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi dell'Insubria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gualtiero Palareti</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bologna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Davide Imberti</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piacenza Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Insubria</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A; PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006 Oct 26;355(17):1780-9. Erratum in: N Engl J Med. 2006 Dec 28;355(26):2797.</citation>
    <PMID>17065639</PMID>
  </reference>
  <reference>
    <citation>Squizzato A, Romualdi E, Ageno W. Why should statins prevent venous thromboembolism? A systematic literature search and a call for action. J Thromb Haemost. 2006 Sep;4(9):1925-7. Review.</citation>
    <PMID>16961599</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <last_update_submitted>August 18, 2011</last_update_submitted>
  <last_update_submitted_qc>August 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi dell'Insubria</investigator_affiliation>
    <investigator_full_name>Walter Ageno</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Statins</keyword>
  <keyword>secondary prevention</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>d-dimer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Fibrin fragment D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

